Bibliography
- Pawlik TM, Ross MI, Johnson MM, Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy. Ann Surg Oncol 2005;12(8):587-96
- Balch CM, Soong SJ, Atkins MB, An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin 2004;54(3):131-49, quiz 182-4
- Creech O Jr, Krementz ET, Ryan RF, Winblad JN. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 1958;148(4):616-32
- Minor DR, Allen RE, Alberts D, A clinical and pharmacokinetic study of isolated limb perfusion with heat and melphalan for melanoma. Cancer 1985;55(11):2638-44
- Klaase JM, Kroon BB, van Geel AN, Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan. Surgery 1994;115(1):39-45
- Thompson JF, Hunt JA, Shannon KF, Kam PC. Frequency and duration of remission after isolated limb perfusion for melanoma. Arch Surg 1997;132(8):903-7
- Cornett WR, McCall LM, Petersen RP, Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol 2006;24(25):4196-201
- Moller MG, Lewis JM, Dessureault S, Zager JS. Toxicities associated with hyperthermic isolated limb perfusion and isolated limb infusion in the treatment of melanoma and sarcoma. Int J Hyperthermia 2008;24(3):275-89
- Thompson JF, Waugh RC, Saw RPM, Kam PCA. Isolated limb infusion with melphalan for recurrent limb melanoma: a simple alternative to isolated limb perfusion. Reg Cancer Treat 1994;7:188-92
- Thompson JF, Kam PC, Waugh RC, Harman CR. Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. Semin Surg Oncol 1998;14(3):238-47
- Beasley GM, Caudle A, Petersen R, A multi-institutional experience of isolated limb infusion: defining response and toxicity in the United States. J Am Coll Surg 2009;208(5):706-15
- Kroon HM, Moncrieff M, Kam PC, Thompson JF. Outcomes following isolated limb infusion for melanoma. A 14-year experience. Ann Surg Oncol 2008;15(11):3003-13
- Santillan AA, Delman KA, Beasley GM, Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis. Ann Surg Oncol 2009;16(9):2570-8
- Kroon HM, Moncrieff M, Kam PC, Thompson JF. Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients. Ann Surg Oncol 2009;16(5):1184-92
- Vrouenraets BC, Eggermont AM, Hart AA, Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone. Eur J Surg Oncol 2001;27(4):390-5
- Krementz ET, Carter RD, Sutherland CM, Regional chemotherapy for melanoma. A 35-year experience. Ann Surg 1994;220(4):520-34, discussion 534-5
- Vrouenraets BC, Kroon BB, Klaase JM, Value of laboratory tests in monitoring acute regional toxicity after isolated limb perfusion. Ann Surg Oncol 1997;4(1):88-94
- Wieberdink J, Benckhuysen C, Braat RP, Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982;18(10):905-10
- Beasley GM, Petersen RP, Yoo J, Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol 2008;15(8):2195-205
- Brady MS, Brown K, Patel A, A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity. Ann Surg Oncol 2006;13(8):1123-9